[1]骆虎,陈建民,黄艳丽,等.骨关节炎患者动脉僵硬度评估及相关影响因素分析[J].实用骨科杂志,2022,28(4):309-312;338.
[2]Hunter DJ.Lower extremity osteoarthritis management needs a paradigm shift[J].Br J Sports Med,2011,45(4):283-288.
[3]Felson DT.Clinical practice.Osteoarthritis of the knee[J].N Engl J Med,2006,354(8):841-848.
[4]Zhang W,Moskowitz RW,Nuki G,et al.OARSI recommendations for the management of hip and knee osteoarthritis,Part Ⅱ:OARSI evidence-based,expert consensus guidelines[J].Osteoarthritis Cartilage,2008,16(2):137-162.
[5]Hochberg MC,Dougados M.Pharmacological therapy of osteoarthritis[J].Best Pract Res Clin Rheumatol,2001,15(4):583-593.
[6]Ohbayashi N,Hoshikawa M,Kimura S,et al.Structure and expression of the mRNA encoding a novel fibroblast growth factor,FGF-18[J].J Biol Chem,1998,273(29):18161-18164.
[7]Ornitz DM,Itoh N.Fibroblast growth factors[J].Genome Biol,2001,2(3):Reviews3005.
[8]Moore EE,Bendele AM,Thompson DL,et al.Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis[J].Osteoarthritis Cartilage,2005,13(7):623-631.
[9]Wang Y,Yang T,Liu Y,et al.Decrease of miR-195 promotes chondrocytes proliferation and maintenance of chondrogenic phenotype via targeting FGF-18 pathway[J].Int J Mol Sci,2017,18(5):975.
[10]Guo P,Wang Y,Dai C,et al.Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/beta-catenin-induced FGF18 expression in hepatocellular carcinoma[J].Oncogene,2018,37(9):1220-1236.
[11]Yao X,Zhang J,Jing X,et al.Fibroblast growth factor 18 exerts anti-osteoarthritic effects through PI3K-AKT signaling and mitochondrial fusion and fission[J].Pharmacol Res,2019(139):314-324.
[12]Chen T,Gong W,Tian H,et al.Fibroblast growth factor 18 promotes proliferation and migration of H460 cells via the ERK and p38 signaling pathways[J].Oncol Rep,2017,37(2):1235-1242.
[13]Yu Z,Lou L,Zhao Y.Fibroblast growth factor 18 promotes the growth,migration and invasion of MDAMB231 cells[J].Oncol Rep,2018,40(2):704-714.
[14]Zhai F,Song N,Ma J,et al.FGF18 inhibits MC3T3E1 cell osteogenic differentiation via the ERK signaling pathway[J].Mol Med Rep,2017,16(4):4127-4132.
[15]Xu N,Wang BH,Zhou Q,et al.Expression of Halo-hFGF18 and study of its effect on differentiation of ATDC5 cells[J].Protein Expr Purif,2019(155):8-14.
[16]Zhao T,Zhao J,Ma C,et al.Evaluation of relationship between common variants in FGF18 gene and knee osteoarthritis susceptibility[J].Arch Med Res,2020,51(1):76-81.
[17]Liu X,D’Cruz AA,Hansen J,et al.Deleting suppressor of cytokine signaling-3 in chondrocytes reduces bone growth by disrupting mitogen-activated protein kinase signaling[J].Osteoarthritis Cartilage,2019,27(10):1557-1563.
[18]Wang XB,Zhao FC,Yi LH,et al.MicroRNA-21-5p as a novel therapeutic target for osteoarthritis[J].Rheumatology,2019,(8):8.
[19]Imamura K,Tachi K,Takayama T,et al.Released fibroblast growth factor18 from a collagen membrane induces osteoblastic activity involved with downregulation of miR-133a and miR-135a[J].J Biomater Appl,2018,32(10):1382-1391.
[20]Yoshimura K,Hosoya T,Fujinami M,et al.Nymphaeol-C,a prenylflavonoid from Macaranga tanarius,suppresses the expression of fibroblast growth factor 18[J].Phytomedicine,2017(36):238-242.
[21]Shu CC,Jackson MT,Smith MM,et al.Ablation of perlecan domain 1 heparan sulfate reduces progressive cartilage degradation,synovitis,and osteophyte size in a preclinical model of posttraumatic osteoarthritis[J].Arthritis Rheumatol,2016,68(4):868-879.
[22]Shimoaka T,Ogasawara T,Yonamine A,et al.Regulation of osteoblast,chondrocyte,and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10[J].J Biol Chem,2002,277(9):7493-7500.
[23]Shu C,Smith SM,Little CB,et al.Use of FGF-2 and FGF-18 to direct bone marrow stromal stem cells to chondrogenic and osteogenic lineages[J].Future Sci OA,2016,2(4):Fso142.
[24]Müller S,Lindemann S,Gigout A.Effects of Sprifermin,IGF1,IGF2,BMP7,or CNP on Bovine Chondrocytes in Monolayer and 3D Culture[J].J Orthop Res,2020,38(3):653-662.
[25]H-ckel S,Zolfaghar M,Du J,et al.Fibrin-hyaluronic acid hydrogel (regenogel)with fibroblast growth factor-18 for in vitro 3D culture of human and bovine nucleus pulposus cells[J].Int J Mol Sci,2019,20(20):5036.
[26]Frerker N,Karlsen TA,Lilledahl MB,et al.Scaffold-free engineering of human cartilage implants[J].Cartilage,2021,13(1_suppl):1237S-1249S.
[27]Gigout A,Guehring H,Froemel D,et al.Sprifermin (rhFGF18)enables proliferation of chondrocytes producing a hyaline cartilage matrix[J].Osteoarthritis Cartilage,2017,25(11):1858-1867.
[28]Huang L,Yi L,Zhang C,et al.Synergistic effects of FGF-18 and TGF-beta3 on the chondrogenesis of human adipose-derived mesenchymal stem cells in the pellet culture[J].Stem Cells Int,2018(2018):7139485.
[29]Chen X,Yamashita A,Morioka M,et al.Integration capacity of human induced pluripotent stem cell-derived cartilage[J].Tissue Eng Part A,2019,25(5-6):437-445.
[30]Marhardt K,Muurahainen N.Development of a disease-modifying OA drug (DMOAD)in knee osteoarthritis:the example of sprifermin[J].Drug Res (Stuttg),2015,65 (Suppl 1):S13.
[31]Hendesi H,Stewart S,Gibison ML,et al.Recombinant fibroblast growth factor-18 (sprifermin)enhances microfracture-induced cartilage healing[J].J Orthop Res,2022,40(3):553-564.
[32]Brett A,Bowes MA,Conaghan PG,et al.Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis:post-hoc analysis from a phase Ⅱ sprifermin study[J].Osteoarthritis Cartilage,2020,28(11):1432-1436.
[33]Hochberg MC,Guermazi A,Guehring H,et al.Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis:The forward randomized clinical trial[J].JAMA,2019,322(14):1360-1370.
[34]Roemer FW,Kraines J,Aydemir A,et al.Evaluating the structural effects of intra-articular sprifermin on cartilage and non-cartilaginous tissue alterations,based on sqMRI assessment over 2 years[J].Osteoarthritis Cartilage,2020,28(9):1229-1234.
[35]Reker D,Kjelgaard-Petersen CF,Siebuhr AS,et al.Sprifermin (rhFGF18)modulates extracellular matrix turnover in cartilage explants ex vivo[J].J Transl Med,2017,15(1):250.
[36]Ellsworth JL,Berry J,Bukowski T,et al.Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors[J].Osteoarthritis Cartilage,2002,10(4):308-320.
[37]Eckstein F,Kraines JL,Aydemir A,et al.Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint:Post-hoc analysis of a randomised,placebo-controlled phase Ⅱ clinical trial[J].Ann Rheum Dis,2020,79(4):525-528.
[38]Eckstein F,Hochberg MC,Guehring H,et al.Longterm structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis:5-year results from the FORWARD study[J].Ann Rheum Dis,2021,80(8):1062-1069.
[39]Roemer FW,Aydemir A,Lohmander S,et al.Structural effects of sprifermin in knee osteoarthritis:a posthoc analysis on cartilage and non-cartilaginous tissue alterations in a randomized controlled trial[J].BMC Musculoskelet Disord,2016(17):267.
[40]Lohmander LS,Hellot S,Dreher D,et al.Intraarticular sprifermin (recombinant human fibroblast growth factor 18)in knee osteoarthritis:a randomized,double-blind,placebocontrolled trial[J].Arthritis Rheumatol,2014,66(7):1820-1831.